The phenotypically plastic neurons of the embryonic mouse striatum were used to explore mechanisms of catecholamine differentiation in culture. De nova transcription and translation of the CA biosynthetic enzyme, tyrosine hydroxylase (TH), was induced in striatal neurons exposed, simultaneously or sequentially, to the growth factor, acidic fibroblast growth factor (aFGF) and a catecholamine. Although dopamine was the most potent aFGF partner (EDSO = 4 PM), a number of substances, including dopamine (Dl) receptor agonists, f3-adrenoceptor agonists, and dopamine uptake inhibitors also trigger TH induction when accompanied by aFGF. However, since none of the receptor antagonists nor transport blockers tested could inhibit dopamine's action, the mechanism remains obscure. Structure-activity analysis suggests that effective aFGF partners all contain an amine group separated from a catechol nucleus by two carbons. Thus, TH expression can be novelly induced by the synergistic interaction of aFGF, and to a lesser extent basic FGF, and a variety of CA-containing partner molecules.
We speculate that a similar association between growth factor and transmitter may be required in development for the differentiation of a CA phenotype in brain neurons.
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Although the differentiation of the nervous system into neurons of specific biochemical class remains an elusory process, clues as to the underlying mechanisms are now emerging. In the PNS, studies have indicated that individual growth factors act as critical determinants of transmitter type (Saadat and Thoenen, 1986; Adler, 1989; Wong and Kessler, 1989; Yamamori et al., 1989; Rohrer, 1992; Howard and Gershon, 1993; Rao and Landis, 1993) . In the brain, however, the initiation of neurotransmitterspecific genes appears to involve more complex mechanisms, requiring the obligatory interactions of multiple signal molecules (Du et al., 1994) . Although growth factors play a prominent role, their cooperation with auxiliary agents is essential. Thus, exposure in culture both to the growth factor, aFGE and an additional unidentified muscle agent (demonstrated not to be hepa-rin) is necessary to trigger novel expression of the normally quiescent TH gene in non-CA neurons of the striatum (Du et al., 1994) . Whether aFGF and its partner substance are also responsible for signaling the constitutive expression of TH in CA neurons is not yet clear. Consistent with the latter notion, however, is the emergence of TH in differentiating CA neurons (Specht et al., 1981) simultaneously with the appearance of aFGF in the developing brainstem (Ferrari et al., 1989; Engele and Bohn, 1991; Fu et al., 1991; Schniirch and Risau, 1991; Wilcox and Unnerstall, 199 1; Nurcombe et al., 1993) . The possibility is thus raised that CA neurons harbor or have local access to all of the agents necessary for their own biochemical differentiation, including, aFGF and its partner molecule. Supporting this proposition is our preliminary finding that an extract of CA neurons, derived from adult substantia nigra (SN) tissue, is indeed capable of inducing TH expression in cultured striatal neurons. SN neurons, in addition to their supply of endogenous aFGF (Engele and Bohn, 199 1; Schniirch and Risau, 199 1; Wilcox and Unnerstall, 1991; Nurcombe et al., 1993) , also contain high concentrations of CA neurotransmitters, conceivably important in aFGF activation. Since biogenic amines are thought to subserve a number of critical functions in fetal development (Coyle, 1972; Lauder, 1988; Mattson, 1988; Meier et al., 1991) their potential participation in the CA differentiation process and probable mechanism of action were explored here. We will show that induction of the CA-specific gene, TH, is mediated by a novel mechanism which requires the convergent actions of both aFGF and, paradoxically, the enzyme's catalytic end products, the CAs. That neurotransmitters might work coordinately with growth factors to initiate (Iacovitti et al., 1989; Iacovitti, 1991) and subsequently modulate (DeVitry et al., 1991; Iacovitti et al., 1992; Louis et al., 1993; Magal et al., 1993; Iacovitti, 1994) their own synthesis could provide an exciting new model for autoregulation during development and thereafter. The possible mechanisms through which various CAs might achieve these effects is discussed.
Materials and Methods
Tissue culture. Pregnant Swiss white mice were purchased from Taconic Lab Animals at 9 d gestation 2 12 hr fertilization day = embryonic day (E) 0. Pregnant dams were anesthetized with pentobarbital on gestational day 13 and the embryos removed. The developing striatum was isolated from the remainder of the brain as described previously (Iacovitti et al., 1989; Du et al., 1994 calf serum (Irvine Scientific) glucose (6 mg/ml), glutamine (204 kg/ ml), and penicillin/streptomycin (100 U/ml). Cells were dissociated by trituration through a reduced bore glass pipette and plated onto glass Lab Tek culture dishes coated with polymerized polyornithine (precoated for 48 hr at room temperature at a concentration of 0.1 mg/ml in 15 mM borate buffer, pH 8.4) and then rinsed with water and air dried 2-4 min. The cellular plating density was approximately 0.5-l X 10" cells/dish. After a 1 d stabilization period in standard media, cultures were incubated overnight in defined media (Bottenstein and Sato, 1979) containing test reagents. The following day cultures were fixed and processed for the immunocytochemical localization of TH unless otherwise stated. TH immunocytochemistry. Cultures were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) and processed with antibodies to TH (1:5000 dilution, kind gift of Dr. T. H. Joh, New York, NY) using the immunoperoxidase/ABC method of staining (Elite Vectakit). Except where stated otherwise, TH induction was determined by counting positively stained cells in 50% off the microscopic fields on the culture dish. This was accomplished with the aid of an eyepiece reticule used at a 10X magnification. To eliminate the possibility that brainstem noradrenergic neurons were inadvertently included in dissected brain tissue, cultures of midbrain neurons were screened with antibodies to the noradrenergic enzyme dopamine-P-hydroxylase. At no time were stained midbrain neurons observed in these cultures.
Pharmacological studies. El 3 mouse striatal neurons were established in culture as described previously (Iacovitti et al., 1989) . Cultures were stabilized 1 d prior to the addition of various reagents to the media (see Table 2 for listing). To examine the role of dopamine receptors (Dl-D5) and adrenoceptors (a and p) in TH induction, cultures were simultaneously treated with test compounds (at a concentration range of I-200 by) and aFGF (10 rig/ml). In other cultures, we evaluated the ability of .test compounds (i.e.: receptor antagonists or transport inhibitors: I-200 U.M) to inhibit TH induced bv aFGF (10 rig/ml) + CA (either DA at'lO'+M or NE at 50-100 p,t+*Culture media-wai supplemented with test reagents 2 hr prior to the addition of TH-inducing agents. The day after the various treatments, all cultures were fixed in 4% paraformaldehyde, immunocytochemically stained for the localization of TH, and scored for TH induction as described previously (Iacovitti et al., 1989) . The results are expressed as the percentage of total neurons which stained positively with antibodies to TH.
Statistical analysis. Data were statistically analyzed by one-way analysis of variance. When P < 0.05, then theF test was followed by the two-tailed Student's t test to compare the statistical significance between control and experimental groups. Differences were considered significant only when the P value was less than 0.05.
Chemical reagents. All transmitter-related compounds, cyclohexamide, and cY-amanitin were purchased from Sigma Chemical (St. Louis, MO). All receptor agonist and antagonists were purchased from RBI (Natick, MA). Growth factors were acquired from the following sources: aFGF, bFGF, and FGF-7 were kind gifts of Amgen; FGF-6 was kindly supplied by Dr. E Coulier (Marseille, France); fiGF was a gift from Dr. E. M. Johnson (St. Louis. MO): CNTF was kindlv suoolied by Scios Nova Inc.; EGE'LIE IL1 'and TGFP were purchaskd f;dm R and D Systems. All reagents used in culture were obtained from GIBco.
Results

Induction of TH by aFGF and CAs
The phenotypically plastic neurons of the El3 mouse striatum were chosen as the model system for these studies since their neurotransmitter profile can be permanently altered by exposure to differentiative cues in culture (Iacovitti et al., 1989; Iacovitti, 1991; Du et al., 1994) . As part of our initial screening, we tested the capacity for a variety of neurotransmitters and related compounds to induce TH in striatal neurons when incubated alone or in combination with aFGE As seen in Table 1 , administration of neurotransmitter substances or aFGF alone had no apparent effect on TH expression. In contrast, the combined treatment of aFGF with transmitters, specifically CA transmitters, resulted in a striking induction in TH in striatal neurons. Dopamine was particularly effective as an aFGF partner (ED,, = 4 FM), initiating the expression of TH in the majority of cultured striatal neurons (Fig. 1) . However, dose-response studies (Fig. 2) re- El3 mouse striatal neurons were established in culture as described previously (Iacovitti et al., 1989) . Cultures were stabilized one day prior to the addition of various neurotransmitter substances to the media (at a concentration range of I-800 p,M). Some of the cultures were simultaneously treated with exogenous aFGF (10 "g/ml). The following day, all cultures were fixed in 4% paraformaldehyde, immunocytochemically stained for the localization of TH, and scored for TH induction as described previously (Iacovitti et al., 1989) . The results are expressed as the percentage of total neurons which stained positively with antibodies to TH. Each value represents the mean + the SD for triplicate cultures in 2 separate platings. ND, not detectable. * ED,,, values were calculated for cultures co-treated with aFGF (IO "g/ml) and l-200 pM neurotransmitter.
vealed that other CA-containing compounds, such as, L-dopa, norepinephrine and epinephrine were also effective, albeit at higher concentrations (ED,, = 25-85 PM). The role of catecholamines in this effect may be important for explaining the low level TH induction sometimes observed when aFGF was added to the media in the absence of exogenous partner molecules (Du et al., 1994) . In all cases of basal TH induction, scattered THimmunoreactive neurons were observed, even in control (untreated) cultures. It is conceivable that the presence in some platings of these spurious TH neurons resulted in the production of low levels of endogenous L-dopa or dopamine which then partially induced TH expression in other neurons when aFGF was added exogenously.
In contrast to CAs, when cultures of striatal neurons were incubated with various concentrations of monoamine precursors or their metabolites (1 .O PM to 200 PM of tyrosine, tyramine, homovanillic acid and 3,Cdihydroxyphenylacetic acid) alone or in combination with aFGF (10 rig/ml), no TH induction was observed (data not shown).
Studies on the mechanism of CA action We next investigated whether CAs mediated their cellular effects through either dopaminergicladrenergic membrane receptors or by direct uptake into the cell via transporter mediated systems. Summarized in Table 2 is a list of receptor agonist and antagonist compounds and transport blockers which were tested in an attempt to either stimulate or inhibit CA assisted TH induction by aFGE All reagents were first evaluated for TH-inducing capacity when administered alone. In no case was TH induced by treatment solely with a receptor agonist, antagonist or uptake blocker (data not shown). To begin to understand the role of dopamine receptors (Dl-D5) and/or adrenoceptors (a and p) in Figure 1 . Immunocytochemical localization of TH in cultured striatal neurons. Neurons were established in culture (Iacovitti et al., 1989; Iacovitti, 1991) 1 d prior to incubation in control media (A) or in media supplemented with 10 nglml aFGF (B), 10 pM dopamine (C); or 10 rig/ml aFGF + 10 p,M dopamine (D). The following day, cultures were fixed and TH was immunocytochemically localized. Note that dopamine, in collaboration with aFGF, produced a striking induction of TH in many of cultured striatal neurons.
mediating TH induction, cultures were simultaneously treated with a maximal inducing dose of aFGF (10 rig/ml) and selective CA receptor agonists/antagonists (see Table 2 listing) at a concentration range of l-200 pM. We found that the DUD5 receptor agonist SKF 38393, in all rotameric conformations (+, -, + ), could successfully substitute for dopamine, inducing TH expression in 60% of those striatal neurons simultaneously treated with aFGE However, pre-and cotreatment with known Dl receptor antagonists (I-200 pM) were unable to block this effect. Neither SCH 23390, apomorphine, haloperidol could inhibit TH induced by aFGF (10 rig/ml) + dopamine (10 FM) or SKF 38393 (10 pM; data not shown). Other dopamine receptor (D2, D3, D4) agonists and antagonists neither stimulated nor inhibited TH expression in striatal neurons. We next tested the potential role of classic adrenergic receptors in TH induction. The B-adrenergic receptor agonist, isoproterenol, similar to NE (reported above), was a potent aFGF partner, inducing TH immunoreactivity in the majority of striatal neurons (Table 2) . Again, however, the B-adrenergic antagonist propranolol was incapable of preventing induction by aFGF and NE or Isoproterenol.
Since it is possible that CAs do not work at the membrane, but rather exert their effects intracellularly following uptake via a neurotransport system, we attempted with known DA uptake blockers (mazindol, nomifensine, etc.) or GABA uptake blockers (nipecotic acid; 1 -amino-1 -cyclohexane carboxylic acid, ACCA) to inhibit TH induction. As we had seen with the receptor antagonists, no uptake compound tested (even at a 20-fold excess concentration; 400 X the IC,,) was able to block induction by aFGF and dopamine (Table 2) . Moreover, selective inhibitors of GABA uptake did not prevent TH induction, suggesting that the GABA transporter is not responsible for taking up CAs in these experiments. Likewise dopamine transport inhibitors could not block, though several (mazindol, GYKI 52895) paradoxically mimicked the effects of dopamine, producing 40% TH induction when co-incubated with aFGE Moreover, in the case of mazindol, the level of induction could be further increased by the addition of dopamine as well as aFGE Although it is possible that mazindol, by blocking reuptake of dopamine, increases extracellular levels of transmitter sufficiently to partner aFGE this does not explain its ability to enhance TH induction when co-incubated with a maximally inducing dose of dopamine. The additive effects of mazindol and dopamine imply that both agents may partner aFGF but their mechanisms of action may differ.
CA activating effect is maximal for aFGF compared to other growth factors In addition to aFGE ongoing studies (Du et al., 1995) suggest that other dopamine differentiation factors, such as brain-derived growth factor (BDNF) (but not glial-derived growth factor), may also possess some ability to induce TH expression in the presence of partner molecules (30% induction). We therefore tested whether other neural growth factors could initiate TH when partnered by CA. Striatal cultures were incubated overnight in media containing aFGF, bFGF, FGF-6, FGF-7, epidermal growth factor (EGF), NGE ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), transforming growth factor B (TGFB), or interleukin 1 (ILI) alone or in combination with 10 pM dopamine. The following day TH induction was evaluated immunocytochemically. Of the growth factors tested, only aFGF, and to a lesser extent, its isoform basic FGF (bFGF) could induce TH expression when dopamine was included in the incubation media (Fig. 3) . Although the maximum level of induction was lower for bFGF than aFGE both growth factors generated nearly identical time courses when incubated with dopamine: TH expression was first evident at 6 hr, peaked by 12 hr and remained elevated even 108 hr following treatment (Fig. 3) .
Synergy does not require co-incubation of aFGF and CAs
In an attempt to localize the synergy between aFGF and its partner molecule, TH induction was compared after the simultaneous or sequential incubation of inducing agents. TH induction was compared in cultures incubated simultaneously with aFGF (10 rig/ml) and (+)SKF 38393 (100 pM) and those which received successive treatments with the individual reagents. In the former group, both reagents were added together for 0.254.0 hr, media was then removed, cultures were rinsed twice for 5 min each and reincubated for the remaining time in defined media (which had not been supplemented with added agents). In the latter group, cultures were treated for various periods of time (0.254.0 hr) with aFGF or (?)SKF 38393, rinsed as above and then re-incubated with the reciprocal agent. The next day, cultures were fixed and stained with TH antibodies. After sequential treatment, induction was observed regardless of whether aFGF was added first and then replaced with (k)SKF 38393 or vice versa (data not shown). However, aFGF required a longer exposure time (4 hr) than did (?)SKF 38393 (30 min) for initiating the effect. When both reagents were added simultaneously to the culture, increased TH expression was also observed within 4 hr of cotreatment. The fact that both aFGF and the dopamine receptor agonist need not be incubated together suggests that the effect occurs independent of conformational changes resulting from their direct molecular interaction. Instead, it appears that convergence of aFGF and its partner occurs inside the cell, possibly along their intracellular signaling pathways.
De novo transcription and translation are required for TH induction by aFGF and dopamine As suggested by our earlier studies (Iacovitti et al., 1989; Iacovitti, 199 1 ) , the induced appearance of immunoreactive TH in striatal neurons, required both de novo transcription and translation. Thus, inhibition of protein synthesis with cyclohexamide decreased in a dose-dependent manner the number of TH immunoreactive neurons elicited by dopamine and aFGF treatment; inhibiting over 90% of TH induction at the maximum dose tested (1000 rig/ml) (Fig. 4) . Preincubation of neurons with the RNA polymerase inhibitor a-amanitin, at a dose range (4 kg/ ml) which totally inhibits RNA polymerase II (Roeder, 1976) , reduced by more than 50% the number of TH immunoreactive neurons (Fig. 4) . Higher concentrations (400 pg/ml) of amanitin which inhibit RNA polymerase III as well (Stott, 1991) , prevented 90% of the usual induction of TH.
Discussion
The results of these studies suggest that, in mammalian brain, as in simpler invertebrate systems (Karin, 1989; Foulkes et al., 1991; Lamb and McKnight, 1991; Bowers, 1994) , gene expression is controlled by the synergistic and competitive interactions of several regulatory factors. Thus, the growth factor aFGF, and to a lesser extent bFGE working in concert with a partner molecule, shown here to be a CA neurotransmitter, will trigger the novel expression of TH in non-CA neurons. This expression requires both de novo transcription of the TH gene and translation of the mRNA into newly synthesized protein.
Mechanism of TH induction
The mechanisms through which the cultured striatal neuron achieves these actions remain elusory. It is presumed but not yet proven that aFGF exerts its effects by binding to one or more of the four high affinity tyrosine kinase-linked membrane receptors (Donne et al., 1991) . CAs, on the other hand, may mediate their cellular actions through several routes. First, CA membrane receptors, including dopamine (DUD2) receptors (Maus et al., 1989; Premont et al., 1983) as well as (Y- (Weiss et al., 1987) and B- (Van Vliet et al., 1991) adrenoceptors present on cultured striatal neurons might activate second messenger systems to bring about TH induction. Indeed, in our studies, agonists of the DUD5 dopamine receptor and the B-adrenergic receptor mimicked the TH inductive effects of dopamine and NE, respectively. However, the fact that specific antagonists of these sites did not inhibit their action (even in concentrations 400X the IC,,) suggests that these receptors are not the mediators of TH induction. Although there is no evidence for the existence of a dopamine transporter (Shimada et al., 1992; Cerruti et al., 1993; Grant et al., 1994) on GABAergic neurons of the adult striatum, we none- El3 mouse striatal neurons were established i n culture as described previously (Iacovitti et al., 1989) . Cultures stabilized one day prior to the addition of various reagents to the media. The ability of compounds to substitute for CA i n TH induction was evaluated by co-treatment of cultures with l -200 pM of the receptor agonist, antagonist, or uptake inhibitor and 10 rig/ml of aFGF (left column). The capacity to block TH induction by aFGF + CA (either dopamine [DA] at 10 p,M or NE at 50P100 PM) was assessed by pretreatment of the cultures for 2 hr with the test compound before the further addition of aFGF (10 rig/ml) + the appropriate CA (10 PM) to the media (right column).
On the day following the various treatments, all cultures were fixed i n 4% paraformaldehyde, immunocytochemically stained for the localization of TH, and scored for TH induction as described previously (Iacovitti et al., 1989 theless tested whether dopamine was gaining access to the cell via an uptake mechanism. When agents known for their ability to block dopamine transporter activity were tested, they did not prevent the induction of TH by aFGF and dopamine. In fact, several dopamine uptake inhibitors were instead inducers of TH when co-incubated with growth factor. This group of apparently disparate aFGF partners (Dl/D5 agonists, P-adrenergic agonists, dopamine uptake inhibitors) share several distinguishing biochemical features; all members contain an amine group separated from a catechol nucleus by two carbons. The fact that these chemical traits are virtually identical to those required for optimal uptake by the dopamine transporter (Meiergerd and Schenk, 1994) raises several possibilities. First, it is conceivable that embryonic striatal neurons contain the dopamine neurotransporter in addition to the usual GABA transporter (Radian et al., 1990) but expression of the former is lost by adulthood. Precedent for the coexistence of GABA and DA transporters on the same cell has indeed been reported previously (Bonanno and Raiteri, 1987) . Alternatively, it is possible that the embryonic GABA transporter possesses recognition and/or translocation sites which are less discriminating than the adult, permitting uptake of dopamine and other related catechols. In view of the fact that it is now believed that the gene family of neurotransporters is far larger than originally suspected (i.e., "orphan" transporters with no known function have been identified) (Uhl, 1987) , an entirely new neurotransporter may account for our results. Regardless of whether striatal neurons possess an embryonic form of the DA or GABA transporter or a new transporter, our results make clear that this site can not be blocked by the usual inhibitors of dopamine or GABA uptake. Finally, we can not overlook the possibility that, since TH induction is not inhibited by classic receptor antagonists or transport blockers and can be initiated by both D and L forms of the receptor agonist SKF 38393, dopamine utilizes a novel mechanism to mediate its effects on striatal neurons. Since the byproducts of lipid peroxidation are known to increase gene transcription and stimulate biochemical differentiation in a variety of developing tissues (Allen, 1991) , one intriguing possibility is that catechols induce TH by increasing lipid peroxidation of the cell membrane. Resolution of these issues awaits further investigation.
Relevance to CA differentiation Whether these in vitro results on the non-CA neurons of the striatum are indicative of an in vivo role for aFGF and catecholamines in initiating TH gene expression in CA neurons is not yet known. Certainly, aFGF is found locally in the brainstem (Ferrari et al., 1989; Engele and Bohn, 1991; Fu et al., 1991; Schniirch and Risau; Wilcox and Unnerstall, 1991; Nurcombe et al., 1993) during the period when CA neurons first differentiate (Specht et al., 1981) . However, the presence of other dopamine differentiation factors, such as BDNE may also prove to be physiologically important for TH activation during development (Du et al., 1995) . Regardless of the growth factor, activation by partner molecules, such as CAs, appears to be a necessary step in TH gene initiation. The requirement for endogenous CAs, however, poses an obvious paradox for neurons attempting to first initiate CA synthesis. Consequently, biogenic amines must originate extraneuronally if they are to act as aFGF partners during differentiation. One potential internal source of CAs might be cells of the PNS (i.e., sympathetic neurons, adrenal medullary cells) which acquire the capacity to synthesize CAs by El 1.5 in the rat (Teitelman et al., 1981) , approximately 1 d before TH first appears in the CNS (Specht et al., 1981 ). An alternative source of CAs are those derived externally from the maternal circulation which cross the placenta to freely permeate the embryonic brain (Saunders and Mollgard, 1984; Lossinsky et al., 1986) . This putative role for CAs in differentiation is indeed consistent with the widely held view that neurotransmitters mediate many critical functions in fetal development (Coyle, 1972; Lauder, 1988; Mattson, 1988; Meier et al., 1991) , including the stimulation of differentiation factor production (Habecker and Landis, 1994) . Nonetheless, we can not eliminate the possibility that CAs are not the physiologically relevant partners during development but are merely mimicking their effects by activating signaling pathways in common with those required for TH induction.
The induction of TH elicited by aFGF and dopamine was mechanistically similar to that seen previously with L6 muscle extract (Iacovitti et al., 1989; Iacovitti, 1991) , requiring both de IZOVO transcription and translation. However, muscle cells, which manufacture their own aFGF, do not synthesize or take up dopamine or related neurotransmitter compounds. It is, therefore, unlikely that the partner molecule present in L6 cells is one of the CA-containing compounds identified here. Implicit in this conclusion is the existence of multiple activators of aFGE some found iri neurons (i.e., CAs), and at least one other present in muscle. Although the required participation of a partner molecule may be useful for restricting the effects of universal growth substances such as aFGF, the availability of several partners could provide the versatility needed to induce the TH gene under a variety of different conditions. Conceivably, these different partner molecules might achieve their effects via activation of one or more of the many important transcription binding sites already identified on the TH gene (Lewis and Chikaraishi, 1987;  5426 Du and lacovitti -Dopamine and aFGF Together Induce Tyrosine Hydroxylase CHX (rig/ml) TT T alpha-Amanitin @g/ml) Figure   4 . Effect of protein and RNA synthesis inhibitors on the TH expression elicited by aFGF and dopamine. Neurons stabilized for 1 d in culture received 0.01-1000 rig/ml cyclohexamide (CHX) to inhibit protein synthesis (A) or 0.25400 yg/ml a-amanitin to inhibit RNA polymerases (B) 2 hr before the addition of 10 FM dopamine, 10 ng/ ml aFGF to the culture media. The following day cultures were fixed and stained for TH. Values are expressed as the percentage of TH positive neurons in the culture. Each value represents the mean + SD of four determinations. Jones et al., 1988; Kemmler et al., 1989; Carroll et al., 1991; Fung et al., 1992; Kim et al., 1993; Murre and Baltimore, 1993) . Consistent with this view is the recent finding that tissue specific expression of TH indeed requires an interaction between two consensus binding sites on the gene .
It is not yet clear whether the same substances that first initiate expression of a quiescent TH gene are also involved in its routine regulation. Although CA transmitters have long been considered feedback inhibitors of the TH enzyme (Nagatsu et al., 1964; Spector et al., 1967; Weiner et al., 1972; Zigmond et al., 1989) , their possible role when combined with the growth factor, aFGF, as feedback inducers of TH has not been explored previously. Thus, as in other systems (Mani et al., 1994) , the cross talk between growth factors and neurotransmitters may be essential for proper regulation of TH at the transcriptional and translational levels.
